Please try another search
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Name | Age | Since | Title |
---|---|---|---|
Kurt J. Hilzinger | 62 | 2015 | Independent Director |
Arun Kumar Pillai | 62 | - | Board Observer |
Julian S. Gangolli | 65 | 2020 | Independent Non-Employee Director |
Faisal G. Sukhtian | 39 | 2017 | Independent Director |
Andong Huang | 26 | 2020 | Independent Director |
Ralph H. Thurman | 74 | 2018 | Independent Executive Chairman |
Yezan M. Haddadin | 47 | 2017 | Independent Director |
Lawrence A. Kenyon | 57 | 2015 | Executive VP, CFO, Treasurer, Company Secretary & Director |
Gerd U. Auffarth | 58 | 2020 | Independent Non-Employee Director |
C. Russell Trenary | 65 | 2021 | President, CEO & Director |
Julia A. Haller | 68 | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review